Accelerating the Fight Against Cancer
At Niowave, we believe that behind every isotope delivered is a patient waiting for treatment. Our work is to make sure the supply behind that therapy is reliable, consistent, and built to scale.
The Niowave Advantage
Niowave’s approach to isotope production is rooted in its early work in superconducting linear accelerator development, before Actinium-225 became a focus across the industry. Our history with accelerator systems and radiochemistry processes has allowed us to develop the expertise needed to support reliable isotope production.
Bringing these disciplines together under one organization allows us to control the process, from beam generation to final isotope distribution, and to improve it continuously over time.
Actinium-225
Actinium-225 is one of the most promising isotopes in targeted alpha therapy, enabling highly localized cell destruction through short-range, high-energy emissions. Its clinical potential has advanced quickly but supply remains limited and it is complex to scale.
Niowave produces Actinium-225 using its in-house accelerator platform supported by integrated radiochemistry and cGMP compliant operations. This approach allows for controlled production and consistent quality as demand continues to grow. Our focus is to support the development and delivery of therapies that depend on a reliable source of Actinium-225.